AGM Presentation

November 12, 2015 Kerry Rowe

2015_11_13 Prana AGM Presentation 2

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM Presentation

Related Posts

Alterity’s lead drug candidate receives positive opinion from European medical agency

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

Prana announces Share Purchase Plan Closed